circPTPRA was shown to suppress the progression of bladder cancer, through its interaction with IGF2BP1, an N6-methyladenosine (m6A) reader, and blocking the IGF2BP1-mediated recognition of m6A-modified RNAs [47]. The gene discussed is IGF2BP1; the disease is urinary bladder cancer.